Abstract
Abstract : We hypothesized that (1) prostate cancer cells that express high levels of cyclooxygenase-2 (COX-2) and prostaglandin E2(PGE2) display enhanced bone targeting and (2) the level of expression of COX-2 and PGE2 in established bone metastases determines the overall bone response, with lower vs. higher levels inducing osteoblastic vs. osteolytic responses, respectively. We utilized two human prostate cancer cell lines (MDA-PCa-2B that expresses low levels of COX-2 and PGE2 and produces osteoblastic lesions vs. PC-3 that expresses high levels COX-2/PGE2 and induces osteolytic mets). We demonstrated that (1) low levels of PGE2 stimulate preosteoblast cell growth, differentiation and Wnt signaling (2) Forced overexpression of COX-2 in MDA-PCa-2b cells induces the Wnt antagonist DKK-1 (3) PGE2 addition to PC-3 cells stimulates Dkk-1 (4) Forced overexpression of COX-2 in MDA-PCa-2B cells inhibits preosteoblastic cell growth in co-culture and, finally, (5) Treatment with a COX-2 inhibitor reduced PC-3 metastatic lesions in vivo after intracardiac inoculation. Over the next several weeks we will analyze bone metastatic lesions to determine overall bone response in vivo from the PC-3 experiments and from tibia of mice inoculated with wild-type vs. COX-2 overexpressing MDA-PCa-2b cells. These studies confirmed our hypothesis that levels of COX-2/PGE2 expression in prostate cancer cells modulates both bone targeting and bone response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.